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Microbiota is an essential community of microorganisms 
that colonize from birth in different areas of the human 
body predominantly gut, oral and nasal mucosa, vaginal 
tract, etc. Is a dynamic population of over a trillion of 
microbes that include bacteria belonging to the different 
families, viruses and fungi that interact one with the other, 
with the local habitat and environment. The microbiome 
is the incredible number of genes that can be extrapolated 
by this complex community of cells being 100-fold larger 
than the whole genome. This fascinating “forgotten 
organ” is known to influence the training of the immune 
system thus affecting several physiological functions of the 
body and several diseases. Moreover, it contributes to the 
establishment of mechanisms for pathogen recognition 
and protection. Several factors are known to influence 
the variable part of the microbiome such as host lifestyle, 
environment, diet, genotype, pathobiology, inflammation, 
etc. Parameters associated with a healthy and fit microbiome 
are essentially the high diversity and a resilient feature, 
i.e., the capacity to cope with a physiological stress. An 
unbalanced scenario together with concomitant factors such 
as an inflammation process and/or presence of pathogens 
can cause complex diseases. Microbiota dysbiosis is thought 
to cause then several disorders such as inflammatory bowel 
diseases but also other systemic diseases like diabetes and 
interestingly central nervous system pathologies (1). In the 
last years the advent of molecular techniques such as next 
generation sequencing (NGS) have given a relevant impulse 
in the characterization of microbiome. Methodologies 
analyzing bacterial 16S rRNA and the more sophisticated 
DNA shotgun sequencing has allowed to perform targeted-
metagenomic and full sequencing analyses of the microbial 
communities, thus defining bacterial phyla, families, genera 
down to species details, hence providing metataxonomic 
maps of microbiota. We now can define the portraits of 
bacteria colonizing the gut during lifetime and alterations 
of the composition linked to several diseases both in term 
of fecal and mucosal microbiota. Specific parameters 
of microbiota profiles, such as ecological biodiversity, 
differences in the relative abundances of taxa as well as 
the cataloguing of microbial sequences into operational 
taxonomic units (OUT) and their correlations can now 
identify microbial signatures associated to inflammation or 
other intestinal and extra-intestinal features and specific 
microbial biomarkers of disease. 
In particular since microbiota is strictly associated 
with immunity and the development of a healthy immune 
system, it was not surprising the finding that outcome 
of immunotherapeutic strategies in cancer patients can 
be dependent on the gut microbiome (2). Treatment of 
cancer with check point inhibitors capable to unleash T 
cells to expand exponentially and kill transformed cells, is 
the newest and best treatment strategy being developed in 
the last decade. A true revolution in oncology is ongoing 
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and we are seeing dramatic responses and long term 
overall survival in critical deadly tumors like advanced 
melanoma, non-small cell lung cancers (NSCLCs), renal 
cell carcinomas (RCCs). Not all patients respond and some 
of them show severe autoimmune toxicities. That response 
to immune checkpoint inhibitors (ICI) therapy, particularly 
anti-CTLA-4, could be associated to microbiome 
composition was first suggested by the group of Zitvogel in 
2015 in melanoma (2). Other groups have confirmed and 
expanded the knowledges also by means of experimental 
models (3). Very recently the observation is being extended 
to epithelial cancers (4). Using shotgun DNA analysis 
performed on fecal samples from 60 NSCLC and 40 RCC 
patients before, during and after ICI therapy, they found 
an overrepresentation of the Firmicutes Akkermansia 
muciniphila present already at diagnosis in patients that 
with the therapy later showed a favorable clinical outcome. 
Moreover, antibiotics could compromise the efficacy of 
PD-1 blockade. Findings were further confirmed using 
the “avatar mice” model where mice were recolonized 
by fecal microbiota transplantation from responder and 
non-responder ICI treated patients. Restored immunity 
and antitumor activity of ICI could be achieved only with 
transplantation of stool samples from responder patients. 
Immunological mechanisms underlying these findings are 
still in the process of being fully elucidated. A specific Th1 
response against A. muciniphila was detected associated with 
prolonged progression-free survival (PFS) in patients and in 
the antibiotic induced dysbiotic mice models the addition of 
Akkermansia was capable to increase T cell recirculation in 
lymph nodes and tumor beds. The close link with antitumor 
Th1 mediated immunity was already demonstrated since 
microbiota stimulated dendritic cells (DCs) are more 
efficient in activating T cell responses (5).
In other reports in the same issue of Science (6,7) 
melanoma patients microbiome was studied and a 
significant association was observed between commensal 
microbiome composition and clinical response of PD-1 
treated patients. In the other report the amount of diversity 
of the microbiome repertoire appeared to be significant in 
defining ICI responder patients (Table 1).
Significance of these findings is quite relevant for 
future strategies in oncology. First of all, the possibility to 
address dysbiotic indexes of microbiota maps, transferring 
translational research data into microbiome analytics, a new 
discipline, intended as microbiome “laboratory medicine”, 
serving as diagnostic tool for microbiome clinics. The next 
step of microbiota profiling need to exploit multi-omics 
approaches, also including metabolomics and proteomics 
in diagnostic algorithms to provide compositional but 
also functional maps of microbiota. From this diagnostic 
level, based on a new system medicine-based strategy, the 
possibility to manipulate microbiome with nutritional 
strategies, probiotics/prebiotics administration, eubiotic 
Table 1 Gut microbiome and response to ICI treatment
Gut microbiome Response to ICI treatment Species Ref.
Bacteroides fragilis, Bacteroides thetaiotamicron 
(Phylum Bacteroidetes)
Immunostimulatory effect of CTLA-4 blockade Mouse/human Vétizou et al., 
2015
Bacteroides spp., Burkholderiales 
(Proteobacteria phulum)
Increased effectiveness of anti-CTLA-4 treatment Mouse Vétizou et al., 
2015
Bifidobacterium spp. (Actinobacteria phylum) Abundant presence in mice that have greater 
response to treatment with anti-PD-1
Mouse Sivan et al., 
2015
Clostridales (Firmicutes phlylum) Presence in responder
patients with metastatic melanoma in treatment 
with anti-PD-1 therapy
Human Gopalakrishnan  
et al., 2018
Akkermansia muciniphila (Phylum 
Verrucomicrobia)
Favorable association with clinical outcome in 
NSCLC and RCC patients treated with anti-PD-1 
MoAb
Human Routy et al., 
2018
Bifidobacterium longum, Collinsella aerofaciens 
(Phylum Actinobacteria); Enterococcus faecium 
(Phylum Firmicutes)
Abundance in metastatic melanoma responder 
patients treated with anti-PD-1
Human Matson et al., 
2018 
ICI, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; MoAb, monoclonal antibody.
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rather than antibiotic control or fecal transplantation can 
now be exploited to increase the prevalence of bacteria 
linked to anticancer immunosurveillance and to adapt 
bacteria ecosystem accordingly. It is necessary to build up 
reference biobanks of disease-associated microbiota profiles 
and fecal transplant dedicated material reservoirs. Variants 
of microbiota “enterophenotypes”, associated to treatments, 
clinical conditions and cancer types should be catalogued 
and stored into reference databases, both available for 
microbiomics scientists and for clinicians (Figure 1). 
Moreover, findings point out once more the important 
link with the development and manipulation of antitumor 
immunity. The immunotherapeutic strategies involving 
ICI that are nearly ready to go into the clinic will have to 
deal with these issues for the need to increase number of 
responder patients, identify optimal timing and schedule 
within standard therapies, decide as to whether perform 
microbiome testing for all cancer patients. 
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Figure 1 Integration of omics data for cancer microbiota dysbiosis tracking: datastore, data trafficking, and derived data warehousing. 
Modified from Putignani et al., 2016 (8). MG, metagenomics; MP, metaproteomics; P, proteomics; MB, metabolomics; HTTPS, Hypertext 
Transfer Protocol over Secure Socket Layer; VPN, virtual private network.
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